培氟沙星临床评价

Clinical evaluation of pefloxacin

培氟沙星治疗１０９３例细菌感染，包括男性６４９例，女性４４４例，平均年龄４３．４岁。病种包括呼吸系统感染、泌尿系统感染、肠道感染、皮肤软组织感染、外科及其它部位感染。服药剂量为０．４～１．２ｇ／ｄ，其中０．４ｇ／ｄ４９８例，０．６ｇ／ｄ９８例，０．８ｇ／ｄ４６８例，平均疗程８ｄ。痊愈率为６５．３％，有效率为９０．８％，细菌清除率为７６．９％。不良反应发生率为９．５％（１０４／１０９３），其中消化系统６２例，神经系统２４例，皮疹、搔痒共１０例，早搏１例，ＡＬＴ升高７例。本试验中６５岁以上患者１５１例，其临床疗效与不良反应发生率与总体相似。培氟沙星不同剂量有效性与安全性分析结果显示，随药物剂量增加，临床疗效和不良反应发生率均增高，统计学分析无明显性差异（Ｐ＞０．０５）。

One thousand and ninty three cases of various bacterial infections were treated with pefloxacin tablets for evaluating its efficacy and safety in fields of respiratory, urinary tract, gastrointestinal, skin soft tissue, surgical and other. Pefloxacin 200￣400mg was given two (or three times) a day for 7￣14d days. 498 cases (45.6%) of them were adminstered a daily dose of 400mg; 468 (42.8%) at a day dose of 800mg. The following results were obtained: the overall efficacy rate was 90.8%, the bacterial clearance rate was 76.9%, the adverse reaction rate was 9.5% (104/1093) respectively. The most common adverse events included gastrointestinal intolerance and nervous system, rashes had been of low incidence. To 151 old patients over 65 years in our clinical trial, the efficacy and safety were similar to that of the above results.